α-Keto acid metabolites of organoselenium compounds inhibit histone deacetylase activity in human colon cancer cells

Carcinogenesis

Volumn 30, Issue 8, 2009, Pages 1416-1423

  Nian, Hui ^a,b   Bisson, William H ^b   Dashwood, Wan Mohaiza ^b   Pinto, John T ^c   Dashwood, Roderick H ^a,b  

^a OREGON STATE UNIVERSITY   (United States)

^b OREGON STATE UNIVERSITY   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA KETO GAMMA METHYLSELENOBUTYRATE; BETA METHYLSELENOPYRUVATE; CASPASE 3; CASPASE 6; CASPASE 7; CASPASE 9; CYCLIN DEPENDENT KINASE INHIBITOR 1; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 8; LIPOCORTIN 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ORGANOSELENIUM DERIVATIVE; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE INHIBITOR 1A; HDAC1 PROTEIN, HUMAN; HDAC8 PROTEIN, HUMAN; HISTONE; HISTONE DEACETYLASE; LUCIFERASE; MESSENGER RNA; OXOACID; REPRESSOR PROTEIN;

ACETYLATION; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL GROWTH; CELL LOSS; CELL VIABILITY; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GENE STRUCTURE; GENE TARGETING; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; CELL CYCLE; CHROMATIN IMMUNOPRECIPITATION; COLON TUMOR; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; FLOW CYTOMETRY; GENETICS; IMMUNOBLOTTING; METABOLISM; NICK END LABELING; PATHOLOGY; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE;

ACETYLATION; APOPTOSIS; CELL CYCLE; CHROMATIN IMMUNOPRECIPITATION; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HISTONE DEACETYLASES; HISTONES; HUMANS; IMMUNOBLOTTING; IN SITU NICK-END LABELING; KETO ACIDS; LUCIFERASES; ORGANOSELENIUM COMPOUNDS; PROMOTER REGIONS, GENETIC; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 69449083759     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp147     Document Type: Article

References (46)

1. Gammelgaard, B. et al. (2008) Complementary use of molecular and element-specific mass spectrometry for identification of selenium compounds related to human selenium metabolism. Anal. Bioanal. Chem. 390, 1691-1706.
2. Ip, C. et al. (2000) Selenium modulation of cell proliferation and cell cycle biomarkers in normal and premalignant cells of the rat mammary gland. Cancer Epidemiol. Biomarkers Prev., 9, 49-54.
3. Unni, E. et al. (2005) Se-methylselenocysteine inhibits phosphatidylinositol 3-kinase activity of mouse mammary epithelial tumor cells in vitro. Breast Cancer Res., 7, R699-R707.
4. Sinha, R. et al. (1999) Effects of methylselenocysteine on PKC activity, cdk2 phosphorylation and gadd gene expression in synchronized mouse mammary epithelial tumor cells. Cancer Lett., 146, 135-145.
5. Zhao, R. et al. (2006) Apoptosis induced by selenomethionine and methioninase is superoxide mediated and p53 dependent in human prostate cancer cells. Mol. Cancer Ther., 5, 3275-3284.
6. Cherukuri, D. P. et al. (2005) Selenomethionine regulates cyclooxygenase-2 (COX-2) expression through nuclear factor-kappa B (NF-kappaB) in colon cancer cells. Cancer Biol. Ther., 4, 175-180.
7. Goel, A. et al. (2006) Selenomethionine induces p53 mediated cell cycle arrest and apoptosis in human colon cancer cells. Cancer Biol. Ther., 5, 529-535.
8. Goulet, A. C. et al. (2005) Selenomethionine induces sustained ERK phosphorylation leading to cell-cycle arrest in human colon cancer cells. Carcinogenesis, 26, 109-117.
9. Ip, C. et al. (2002) New concepts in selenium chemoprevention. Cancer Metastasis Rev., 21, 281-289.
10. Cooper, A. J. et al. (2008) Substrate specificity of human glutamine transaminase K as an aminotransferase and as a cysteine S-conjugate beta-lyase. Arch. Biochem. Biophys., 474, 72-81.
11. Sekhavat, A. et al. (2007) Competitive inhibition of histone deacetylase activity by trichostatin A and butyrate. Biochem. Cell Biol., 85, 751-758.
12. Butler, L. M. et al. (2002) The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc. Natl Acad. Sci. USA, 99 11700-11705.
13. Glaser, K. B. et al. (2003) Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: Defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther., 2, 151-163.
14. Kumagai, T. et al. (2007) Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int. J. Cancer, 121, 656-665.
15. McLaughlin, F. et al. (2004) Histone deacetylase inhibitors open new doors in cancer therapy. Biochem. Pharmacol., 68, 1139-1144.
16. Okamoto, H. et al. (2006) Trichostatin A, an inhibitor of histone deacetylase, inhibits smooth muscle cell proliferation via induction of p21(WAF1). J. Atheroscler. Thromb., 13, 183-191.
17. Dashwood, R. H. et al. (2007) Dietary histone deacetylase inhibitors: From cells to mice to man. Semin. Cancer Biol., 17 363-369.
18. Druesne, N. et al. (2004) Diallyl disulfide (DADS) increases histone acetylation and p21(waf1/cip1) expression in human colon tumor cell lines. Carcinogenesis, 25, 1227-1236.
19. Lea, M. A. et al. (2001) Induction of histone acetylation in mouse erythroleukemia cells by some organosulfur compounds including allyl isothiocyanate. Int. J. Cancer, 92, 784-789.
20. Lea, M. A. et al. (2002) Induction of histone acetylation and inhibition of growth of mouse erythroleukemia cells by S-allylmercaptocysteine. Nutr. Cancer, 43, 90-102.
21. Myzak, M. C. et al. (2006) Histone deacetylases as targets for dietary cancer preventive agents: Lessons learned with butyrate, diallyl disulfide, and sulforaphane. Curr. Drug Targets, 7, 443-452.
22. in mice. FASEB J., 20, 506-508.
23. Myzak, M. C. et al. (2004) A novel mechanism of chemoprotection by sulforaphane: Inhibition of histone deacetylase. Cancer Res., 64, 5767-5774.
24. Nian, H. et al. (2008) Allyl mercaptan, a garlic-derived organosulfur compound, inhibits histone deacetylase and enhances Sp3 binding on the P21WAF1 promoter. Carcinogenesis, 29, 1816-1824.
25. Somoza, J. R. et al. (2004) Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure, 12, 1325-1334.
26. Cardozo, T. et al. (1995) Homology modeling by the ICM method. Proteins, 23, 403-414.
27. Totrov, M. et al. (1997) Flexible protein-ligand docking by global energy optimization in internal coordinates. Proteins, (suppl. 1), 215-220.
28. Datto, M. B. et al. (1995) Functional analysis of the transforming growth factor beta responsive elements in the WAF1/Cip1/p21 promoter. J. Biol. Chem., 270, 28623-28628.
29. Vannini, A. et al. (2004) Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc. Natl Acad. Sci. USA, 101, 15064-15069.
30. Rocchi, P. et al. (2005) p21Waf1/Cip1 is a common target induced by shortchain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells. Oncol. Rep., 13, 1139-1144.
31. Nian, H. et al. (2009) Modulation of histone deacetylase activity by dietary isothiocyanates and allyl sulfides: Studies with sulforaphane and garlic organosulfur compounds. Environ. Mol. Mutagen., 50 213-221.
32. Chiba, T. et al. (2004) Identification of genes up-regulated by histone deacetylase inhibition with cDNA microarray and exploration of epigenetic alterations on hepatoma cells. J. Hepatol., 41, 436-445.
33. Miyanaga, A. et al. (2008) Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: Development of a molecular predictive model. Mol. Cancer Ther., 7, 1923-1930.
34. Tavares, T. S. et al. (2008) Gene microarray analysis of human renal cell carcinoma: The effects of HDAC inhibition and retinoid treatment. Cancer Biol. Ther., 7, 1607-1618.
35. Davis, C. D. et al. (2002) Selenium-enriched broccoli decreases intestinal tumorigenesis in multiple intestinal neoplasia mice. J. Nutr., 132, 307-309.
36. Finley, J. W. et al. (2000) Selenium from high selenium broccoli protects rats from colon cancer. J. Nutr., 130, 2384-2389.
37. Finley, J. W. et al. (2001) Cancer-protective properties of high-selenium broccoli. J. Agric. Food Chem., 49, 2679-2683.
38. Davis, C. D. et al. (1999) The chemical form of selenium influences 3, 2′-dimethyl-4-aminobiphenyl-DNA adduct formation in rat colon. J. Nutr., 129, 63-69.
39. Feng, Y. et al. (1999) Dietary selenium reduces the formation of aberrant crypts in rats administered 3, 2′-dimethyl-4-aminobiphenyl. Toxicol. Appl. Pharmacol., 157, 36-42.
40. Reddy, B. S. et al. (2000) Lack of chemopreventive efficacy of DL-selenomethionine in colon carcinogenesis. Int. J. Mol. Med., 5, 327-330.
41. Ip, C. et al. (2000) Chemical speciation influences comparative activity of selenium-enriched garlic and yeast in mammary cancer prevention. J. Agric. Food Chem., 48, 2062-2070.
42. Spallholz, J. E. et al. (2001) Dimethyldiselenide and methylseleninic acid generate superoxide in an in vitro chemiluminescence assay in the presence of glutathione: Implications for the anticarcinogenic activity of L-selenomethionine and L-Se-methylselenocysteine. Nutr. Cancer, 40, 34-41.
43. Gopalakrishna, R. et al. (2001) Protein kinase C as a molecular target for cancer prevention by selenocompounds. Nutr. Cancer, 40, 55-63.
44. Cooper, A. J. (2004) The role of glutamine transaminase K (GTK) in sulfur and alpha-keto acid metabolism in the brain, and in the possible bioactivation of neurotoxicants. Neurochem. Int., 44, 557-577.
45. Lee, J. et al. (2009) α-Keto acid metabolites of naturally-occurring organoselenium compounds as inhibitors of histone deacetylase in human prostate cancer cells. Cancer Prev. Res. in press.
46. Lippman, S. M. et al. (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA, 301, 39-51.